Conclusion. Lefamulin demonstrated potent in vitro antibacterial activity against S. aureus from children with CF, regardless of resistance phenotype. Lefamulin may represent a valuable treatment option for CF patients with S. aureus LRT infections.

Antimicrobial S. aureus (224) MIC (mg/L)
Agent MIC90% (mg/L) MIC50% (mg/L) a
Lefamulin 0.06/0.12 99.6 >0.06/0.12 100.0
Azithromycin 0.06/0.12 48.7 >0.06/0.12 23.5
Clindamycin 0.05/0.06 95.1 0.06/0.02 82.4
Doxycycline ≤0.006/0.0 99.1 ≤0.006/0.0 98.9
Levofoxacin 0.25/0.5 80.4 >0.25/0.5 64.7
Lincomycin 1.0/2.0 100.0 1/1 100.0
Oxacillin 0.1/0.2 77.2 >0.02/0.0 2.0
TMP-SMX ≥0.5/0.5 99.6 ≥0.5/0.5 98.9
Vancomycin 0.01 100.0 1/1 100.0

Disclosures. Helio S. Sader, MD, PhD, FIDSA, Abbvie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support)Contract No. NSF-H1001201600002(C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Shionogi (Research Grant or Support)Susanne Paulner, PhD, Nabriva Therapeutics GmbH (Employee) Steven P. Gelone, PharmD, Nabriva Therapeutics US, Inc. (Employee) S J Ryan Arends, PhD, Abbvie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)GlaxoSmithKline Therapeutics, LLC (Grant/Research Support)Martin Skorupa, PhD (Grant/Research Support)E. Mendes, PhD, Abbvie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContracFect Corporation (Research Grant or Support)GlamoxSmithKline, LLC (Research Grant or Support)GlaxoSmithKline Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support)Telavancin Therapeutics, LLC (Consultant)

1321. Acquisition and Transmission of Streptococcus pneumoniae in Individuals Over the Age of 60 Years Residing in New Haven, CT, USA
Anne Wylie, PhD;1 Sidnya Mboob, n/a;2 Devyn Yolda-Carr, B.S. Microbiology and Molecular Genetics;3 Darani A. Thammavongsa, B.S.;2 Pari Waghela. Master of Science in Biology;2 Maura Nakahata, MPH;1 Noel J. Vega, MS in Microbiology;2 Anna York, PhD;4 Orchid M. Allicock, PhD, Ronika Alexander-Parrish, RN, MAEd,5 Adriano Arguedas, MD;6 Bradford D. Gessner, MD, MPH;5 Daniel Weinerberger, PhD;5 Maikel Hiplop, n/a;3 Yale School of Medicine, New Haven, Connecticut;3 Yale School of Public Health, New Haven, Connecticut;6 Yale University, New Haven, Connecticut;5 Pfizer, Inc, Bowie, MD;5 Pfizer, Inc, Collegville, Pennsylvania;5 Pfizer Vaccines, Collegville, PA

Session: P-73. Respiratory Infections - Bacterial

Background. Despite the widespread use of pneumococcal conjugate vaccines, particularly in children, an important burden of pneumococcal disease remains in older adults. The acquisition and transmission rates of pneumococcus between older adults have not been well characterized.

Method. Beginning October 2020–June 2021, couples living in the Greater New Haven Area were enrolled if both individuals were over the age of 60 years and did not have any individuals under the age of 60 years living in the household. Saliva samples and questionnaires regarding social patterns and medical history were obtained every 2 weeks for a period of 10 weeks. Following culture-enrichment, extracted DNA was tested using qPCR for pneumococcal-specific sequences piaB and lytA. Individuals were considered positive for pneumococcal carriage when qPCR Ct-values for piaB ≥ lytA were less than 40.

Results. To date, we have collected 495 saliva samples from 95 individuals (48 households). Of 495 saliva samples, 31 (5.9%) have tested positive for pneumococcus by either piaB only (n=9) or both piaB and lytA (n=22). Of 495 individuals, 16 (16.8%) (representing 13, or 27.1% households) have tested positive at least once. Six of the 16 (37.5%) carriers tested positive at multiple timepoints, though none were colonized at all 6 time points over the course of the 10 weeks of study enrolment. For 3 of the 48 (6.3%) households, both members of the couple were identified as carriers, though not necessarily at the same sampling moment.

Conclusion. The preliminary findings of this longitudinal transmission model demonstrate evidence of pneumococcal acquisition among older adults measured by molecular tools. These transmission patterns and high rates of pneumococcal carriage in adults were observed during a period when the COVID-19 pandemic led to numerous preventative public health measures that may have reduced pneumococcal transmission (e.g., increased distancing, mask wearing, bans on mass gatherings, restaurant closures, travel restrictions).

Disclosures. Anne Wylie, PhD, Global Diagnostic Systems (Consultant)Pfizer (Advisor or Review Panel member, Research Grant or Support)Pfizer (Consultant,Tempus Labs, Inc (Research Grant or Support)Ronika Alexander-Parrish, RN, MAEd, Pfizer (Employee, Shareholder) Adriano Arguedas, MD, Pfizer (Employee) Bradford D. Gessner, MD, MPH, Pfizer Inc, (Employee) Daniel Weinerberger, PhD, Affinex (Consultant,Merck (Consultant, Grant/Research Support)Pfizer (Consultant, Grant/Research Support)Spero (Consultant, Grant/Research Support)Telavancin (Consultant, Grant/Research Support)

1322. Complications and Hospital Resource Utilization among Patients with Bacterial Nosocomial Pneumonia in the US, 2012-2019
Marya Zilbergber, MD, MPH1, Brian Nathanson, PhD2, Laura A. Puzniak, PhD2, Noad Lahav, n/a,4 Andrew F. Shorr, MD, MPH, MBA,4 Nabriva Therapeutics Group LLC, Goshen, MA;6 OptiStatim, LLC, Longmeadow, MA;5 Merck & Co., Inc., Kenilworth, New Jersey;4 EvMed Research Group, LLC & University of Massachusetts, Amherst, Amherst, Massachusetts;5 Medstar Washington Hospital Center, Washington, DC

Session: P-73. Respiratory Infections - Bacterial

Background. Nosocomial pneumonia (NP) remains a costly complication of hospitalization. Consisting of hospital-acquired ventilated (vHABP) and non-ventilated (nvHABP), and ventilator-associated (VABP) bacterial pneumonia, these conditions themselves are fraught with further complications. We examined hospital resource utilization (HRU) and the rates of important complications in these three groups in a large US database.

Methods. We conducted a multicenter retrospective cohort study within Premier Research database, a source containing administrative, pharmacy, and microbiology data. The three types of NP were identified based on a slightly modified, previously published ICD-9-10-CM algorithm,1 and compared with respect to hospital costs, length of stay (LOS) and development of C. difficile infection (CDI), exubration failure (EF), and reintubation (RT). CDI was identified by its treatment with metronidazole, vancomycin, or fidaxomicin. Marginal effects were derived from multivariable regression analyses.

Results. Among 17,819 patients who met the enrollment criteria, 26.5% had vHABP, 25.6% vHABP, and 47.9% VABP. Patients with vHABP were oldest (mean 66.7+/-15.1 years) and those with VABP were youngest (59.7+/-16.6 years). vHABP was associated with the highest chronic disease burden (mean Charlson score 4.1+/-2.8) and VABP was associated with lowest (3.2+/-2.5). Patients with vHABP had lowest severity of acute illness (ICU 58.0%, vasopressors 7.7%), and those with vHABP were most likely to require vasopressors (38.8%). The adjusted EF and RT in vHABP and VABP, and CDI rates, and adjusted post-infection onset hospital LOS across all groups were similar. The adjusted marginal post-infection onset ICU LOS and total hospital costs relative to nvHABP were 5.9 (95% CI 5.4, 6.3) days and $6,814 (95% CI $3,637, $9,991) in vHABP, and 6.5 (95% CI 6.0, 6.9) days and $16,782 (95% CI $13,146, $20,118) in VABP.

Conclusion. Both vHABP and VABP remain associated with significant morbidity and mortality in the US. VABP was associated with the longest post-infection ICU LOS and highest hospital costs.

Reference. 1. Zilbergber et al. Chest 2019:155:1119:40

Disclosures. Marya Zilbergber, MD, MPH, Cleveland Clinic (Consultant)J&K (Shareholder)Lungpacer (Consultant, Grant/Research Support)Merck (Grant/ Research Support)iscPharma (Consultant)Sedana (Consultant, Grant/Research Support)Spero (Grant/Research Support)Brian Nathanson, PhD, Lungpacer (Grant/Research Support)Merck (Grant/Research Support)Pfizer (Employee) Laura A. Puzniak, PhD, Merck & Co., Inc. (Employee) Andrew F. Shorr, MD, MPH, MBA, Merck (Consultant)